// App-Quantinova.ai

POS0670 (2021) : ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LONG-TERM UPADACITINIB THERAPY

Researchers

Presenter

  • M. Bergman

Principal Investigators

  • M. H. Buch

  • Y. Tanaka

  • G. Citera

  • S. Bahlas

  • E. Wong

  • Y. Song

  • N. Tundia

  • J. Suboticki

  • V. Strand

Medical Centers

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • School of Biological Sciences, University of Manchester and NIHR Manchester Biomedical Centre, Centre for Musculoskeletal Research, Manchester, United Kingdom

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

  • King Abdulaziz University, Jeddah, Saudi Arabia

  • Queen Alexandra Hospital, Portsmouth, United Kingdom

  • AbbVie Inc, Immunology, Illinois, United States of America

Locations

  • United States

  • United Kingdom

  • Japan

  • Argentina

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Placebo Control

  • Active Comparator

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved